Katsuyuki Fukutake

Factor VIII–Mimetic Function of Humanized Bispecific Antibody in Hemophilia A

Midori Shima, Hideji Hanabusa, Masashi Taki et al. · New England Journal of Medicine · 2016 · 449 citations · Full text

Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study

Steven W. Pipe, Midori Shima, Michaela Lehle et al. · The Lancet Haematology · 2019 · 373 citations · Full text

Haven 4, Hematology, Non-randomised Phase 3 +2

Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression

Huanliang Liu, David Chao, Emi E. Nakayama et al. · Proceedings of the National Academy of Sciences · 1999 · 334 citations

Platelets with 10% of the normal amount of glycoprotein VI have an impaired response to collagen that results in a mild bleeding tendency

Morio Arai, Naomasa Yamamoto, Masaaki Moroi et al. · British Journal of Haematology · 1995 · 159 citations

Platelet Gpvi, Immunology, Glycoprotein Vi +23

Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors

Midori Shima, Hideji Hanabusa, Masashi Taki et al. · Blood Advances · 2017 · 122 citations · Full text

Phase 1/2, Thrombosis, Translational Medicine +14